ASH 2024 | A Phase II trial of mosunetuzumab plus polatuzumab vedotin in R/R LBCL

So this study kind of enrolled 80 patients, 40 patients with each arm. One of the probably most remarkable things is that the overall response was about 80% with over 50% patients with complete responses. There was durability that was important and also the progression-free survival was significantly prolonged with a combination of mosunetuzumab and polatuzumab. Another remarkable thing about the study was it was fully outpatient. You know, even for aggressive lymphomas. All the available bispecific antibodies require hospitalization, but this one was fully outpatient treatment. And also the toxicity profile was very favorable. You know, the all-grade CRS was less than 15% which is kind of remarkable. If we see across all the bispecifics, even combinations, the majority have close to 50-60% all-grade CRS. Low utilization of tocilizumab, low utilization of corticosteroids. So in terms of durability of response, the progression-free survival was not reached in comparison to you could compare with polatuzumab rituximab, which was about six months. So I think in conclusion I think that this is an excellent regimen, efficacious, leads to durability of response and it probably is a regimen that may fit the needs of community oncology, you know, because patients don’t require admission, low rate of CRS, low utilization of resources.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.